Impact of additional chromosomal abnormalities in patients with acute promyelocytic leukemia: 10-year results of the Japan adult leukemia study group APL97 study

Haematologica

Volumn 96, Issue 1, 2011, Pages 174-176

  Ono, Takaaki ^a   Takeshita, Akihiro ^a   Iwanaga, Masako ^b   Asou, Norio ^c   Naoe, Tomoki ^d   Ohno, Ryuzo ^e  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^c KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Acute promyelocytic leukemia; Additional chromosomal abnormalities; ATRA; Chemotherapy; Prognosis

Indexed keywords

CYTARABINE; IDARUBICIN; RETINOIC ACID;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME G BAND; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CLINICAL FEATURE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; JAPAN; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROMYELOCYTIC LEUKEMIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 15; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; REMISSION INDUCTION; SURVIVAL RATE; TIME FACTORS; TRANSLOCATION, GENETIC; TRETINOIN; YOUNG ADULT;

EID: 78650980118     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.030205     Document Type: Letter

References (12)

1. Sanz MA. Treatment of acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program. 2006:147-55.
2. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113(9):1875-91.
3. Sanz MA, Lo Coco F. Standard practice and controversial issues in front-line therapy of acute promyelocytic leukemia. Haematologica. 2005;90(6):840-5.
4. Asou N, Kishimoto Y, Kiyoi H, Okada M, Kawai Y, Tsuzuki M, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood. 2007;110(1):59-66.
5. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92(7):2322-33.
6. De Botton S, Chevret S, Sanz M, Dombret H, Thomas X, Guerci A, et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol. 2000;111(3):801-6.
7. Hernandez JM, Martin G, Gutierrez NC, Cervera J, Ferro MT, Calasanz MJ, et al. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA. Haematologica. 2001;86(8):807-13.
8. Schlenk RF, Germing U, Hartmann F, Glasmacher A, Fischer JT, del Valle y Fuentes F, et al. High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia. 2005;19(6):978-83.
9. Cervera J, Montesinos P, Hernandez-Rivas JM, Calasanz MJ, Aventin A, Ferro MT, et al. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with alltrans retinoic acid and chemotherapy. Haematologica. 2010;95(3): 424-31.
10. Schoch C, Haase D, Haferlach T, Freund M, Link H, Lengfelder E, et al. Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients. Br J Haematol. 1996;94(3):493-500.
11. Callens C, Chevret S, Cayuela JM, Cassinat B, Raffoux E, de Botton S, et al. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia. 2005; 19(7):1153-60.
12. Gale RE, Hills R, Pizzey AR, Kottaridis PD, Swirsky D, Gilkes AF, et al. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood. 2005;106(12):3768-76.